We would love to hear your thoughts about our site and services, please take our survey here.
im getting bid of 35 with II on a dummy sale so it looks like this is just a manufactured drop
Great RNS and just shows how Foralumab is gaining accelerated interest within the bioscience world and also shows that Tiziana are not solely dependant on their own pipeline and FDA approval. Whatever the upfront payment is IMO is not as important at this stage as getting the name of Foralumab out there and with Precision willing to share the risk and make an investment whilst developing their own pipeline gives extra confidence. to the market
Dr Fauci is shouting out about the use of monoclonal antibodies so could be helping us even though he recommends treatment before someone is hospitalised
https://nypost.com/2021/08/24/fauci-early-use-of-monoclonal-antibodies-can-reduce-hospitalization-death/
You will probably find that side of the plans has already informally been sorted with institutional investors approval even if tis off record. As they stated its a direct listing then there is no costly underwriters and dilution and roadshows etc involved plus no cash raise so they must be confident with the team and experience they have to carry out the re org. I can't see them making such announcements without knowing the likelihood of being accepted.
Whats more important is having some news ready before the opening day especially with them needing shareholders approval and a general meeting due then I would think that's the only hurdles they have to get by.
I questioned that to myself earlier and they also said there will not be any additional share issued along side the listing. Obviously it was unexpected news as we thought that the main listing would have been successful and now caused a lot of justified tension.
Looking ahead IMO it looks like a positive move as the Nasdaq has a reputation for high growth and a lot of big players are re listing there .
But now the news of intent is out pending shareholders approval im hoping they can now kick start the phase 2 trials as this was said to be liniment and bring some needed exposure and value.pre Nasdaq listing date.
Im also expecting it will be only the consolidated shares on offer as its a direct listing and not an IPO to raise cash. Time will tell
The Board believes that listing shares on NASDAQ directly, as opposed to maintaining its current listing of ADSs, will provide for greater analyst coverage, liquidity and reduce costs for shareholders.
https://corporatefinanceinstitute.com/resources/knowledge/finance/direct-listing/
. Yes ADRs can be listed on Nasdaq but they are not disputing that and at this stage there maybe no need to raise capital just preserve it that benefits shareholders.
Ignore the share price unless you need your money now. The current downtrend in the price doesn't reflect on the real value and potential of the company. With phase 2 trials due to begin shortly this is when Big Pharma begin to take a closer look (if they are not doing it already). You will find that the company are doing their best to protect their pipelines real value and have no control of what price the MMs are at. Any good news release doesn't guarantee a share price rerate straight away as this will be played right up to the last minute. Frustrating yes but don't let it cloud your judgement remember the demerger of Stemprinter was with shareholders approval so we have to trust them to carry out their plans even though its left us open to more manipulation.
The Safe Banking Act in the US if this is eventually passed this will significantly give confidence in the global market .
Hopefully its more like a false drop to shake some weak ones off .
On the cash burn and the potential impact of any future cash raise and extra dilution if needed. But just have to remind ourselves that GC stated that any future cash raise would be done at a considerably higher price so I would expect more encouraging results by then. Just remember that biotech companies generate revenue at a later stage but every week that goes by is a week closer to that goal and an improved pipeline and IMO at some point the MMs will have to rerate the price with only 195M shares and that could happpen at anytime with or without news .Just be patient and hold onto yours as news flow could be more sensitive now and when's the best time to release it but at the same time the MMs have to consider how long can they keep the price low ?
https://finance.yahoo.com/finance/news/heres-why-were-not-too-055619287.html
Now the wider economy is set to open with restrictions lifted their plan is heavily reliant on continued vaccine uptake but with infection rates rising then to sustain their plan I would expect this is where treatments will be heavily relied on more to support the NHS especially going into autumn. Foralumab as a take home treatment is in a great position to support their plan and help to mitigate the risk of going into another lockdown but still would be relevant if things spiralled out of control and their plan was eventually abandoned. So hopefullyTILs grant application will be successful in the near future and Foralumab forms part of the governments longer term plans.
https://canex.co.uk/sajid-javid-health-secretary-medical-cannabis-reform-uk/
Sajid Javid is now Secretary of Health and there’s of mention of him in this GMTV discussion and his support for Medicinal Cannabis so let’s hope he can now give it a push and get regulation in place under his watch https://youtu.be/U-OxmGSoD6U
Imperial Brands are not going to throw their money and have their name connected with this for nothing .
There's a good explanation about valuations when in phase 2 & 3 and when Big Pharma are more attracted to the smaller biotech companies. Mind you the speed of the FDA approval process is worth watching but I expect that Tiziana are one of those companies under the radar with their groundbreaking pipeline of treatments
https://www.cnbc.com/video/2021/06/24/why-there-is-opportunity-in-biotech-and-the-names-to-watch.html
Great new onwards and upwards however I wonder what the terms of the agreement are as Baker Hughes are an established company offering a lot of expertise and support. Possibly more dilution at hopefully an higher price
This trial or whatever you want to call it has FDA approval so there is nothing fraudulent going on as they stated it was being carried out ( Under an Individual Patient Expanded Access Program). Positive results will contribute to more FDA approval further down the line and also attract bigger investment.
https://www.fda.gov/drugs/investigational-new-drug-ind-application/physicians-how-request-single-patient-expanded-access-compassionate-use
Getting their news out first before Oxford Cannabinoids Technologies IPO tomorrow but there a mention of KNB so any excitement should draw some attention their way too.
https://www.marketwatch.com/story/cannabinoid-company-backed-by-rapper-snoop-dogg-headed-for-london-ipo-11621343613
They will mention phase 2 covid trials once and when they are in a position to do so . As they have a 17 month window before any potential future cash raise then as important as covid treatment maybe, they still have to evaluate what direction with limited cash burn is the most effective way forward on gaining success whilst facilitating a cash raise at potentially a higher price. For eg if Phase 2 trials for Crohns diease begins before any phase 2 covid announcement is declared is it really a problem even though there's an expectation. The main thing from here is the results are out now so expect some announcements shortly on the next stages of their pipeline but they just may not be in the order some may anticipate.Moving forward I expect the share price will rise but with the usual price manipulation along the way.We are at an important time now where progress reduces risk and that contributes to the company value hence potential price rise so don't let the negativity cloud your judgement. Good Luck
Lets see where the price is once Phase 2 trials have been announced to begin. I believe it won't be this low no matter how much they try to manipulate the current situation.
Its just about having patience and allowing the company carry out the work required to ensure FDA approval . Remember Phase 2 trials represents reduced risk adding more value and with only 195M shares currently in play the MMs are trying to get them off you now before we get there. Be prepared if successful that we most likely will go through the same long drawn out process between Phase 2 and 3 but im sure the price will be at a far higher level and any additional fund raises if required..